Suramin

Suramin is a synthetic small molecule, not a peptide. It was built at Bayer in the 1910s as one of the first drugs designed through a systematic chemistry program and has been used against African sleeping sickness since the 1920s ². Its structure is a polysulfonated naphthylurea carrying six negatively charged sulfonate groups, which makes it highly water soluble and lets it stick to many positively charged protein pockets ¹.

The only approved indication is early-stage infection with Trypanosoma brucei rhodesiense, the parasite that causes East African sleeping sickness ². Because it also blocks purinergic signaling and other inflammatory pathways, researchers have investigated it for autism, cancer, viral infection, kidney injury, osteoarthritis, and neurological disease. Human evidence includes a small randomized trial in children with autism ⁴ and phase I/II cancer studies ⁵; most other leads remain preclinical.

Suramin is given by injection. It has negligible oral absorption and poor brain penetration, and it clears from the body very slowly. Those properties shape both its long dosing intervals and its toxicity monitoring requirements ¹.

Suramin works mainly as a charged decoy. Its six sulfonate groups mimic the negative charge of DNA, RNA, and sulfated sugars, so the molecule slips into positively charged binding pockets on many unrelated proteins ¹. This is the root of both its broad activity and its off-target burden.

Purinergic receptor blockade

The canonical mechanism is reversible competitive blockade of P2 purinergic receptors, the cell-surface receptors that detect ATP released during stress or injury. This was first characterized at P2X receptors in mouse tissue ³⁵. Structural work shows suramin binds near the ATP pocket, using basic amino acids in a cysteine-rich loop of the receptor, and keeps the channel in a closed state ³⁶. Blocking P2X7 and P2X4 signaling reduces NLRP3 inflammasome assembly, limits pyroptosis, and restores mitochondrial recycling in a Parkinson's model ¹¹. The trade-off is that purinergic signaling is also needed for tissue repair: animal studies show suramin can delay wound closure, new blood vessel growth, and collagen deposition ³⁰.

Beyond P2 receptors

Suramin also uncouples G proteins from their receptors, which silences signaling without occupying the hormone or neurotransmitter binding site ³⁸. It blocks growth-factor receptor docking, including FGF1 binding to FGFR2 ³⁹, and it disrupts several intracellular enzymes: PI3K p85α ¹⁰, IP5 kinase ²⁴, cGAS ²³, pyruvate kinase ⁴⁰, and the DNA replication protein Mcm10 ⁴¹. It binds mitochondrial carriers and enzymes in the energy production chain ¹, and it grabs the tissue-protective protein TIMP-3, keeping it outside cells where it can restrain cartilage breakdown ¹³. It also neutralizes histones released by dying cells ²².

Pharmacokinetics

Suramin is injected, not taken by mouth. It binds strongly to albumin, accumulates in lysosomes, and is excreted very slowly; cattle studies show a terminal half-life of roughly 200-289 hours after a single IV dose ⁴². Human elimination is slower still, on the order of weeks, so clinical protocols use intermittent dosing and monitor plasma levels in a 10-50 µM window ¹.

Approved and clinical results

• Sleeping sickness: Suramin remains a first-line treatment for early-stage T. b. rhodesiense infection. It enters the parasite through the ISG75 receptor, and resistant strains can use a variant surface glycoprotein to sequester it ².
• Autism spectrum disorder: In a double-blind, placebo-controlled pilot, 10 boys received one low IV dose of 20 mg/kg. The trial met safety endpoints and reported signal on core symptom scales, but no phase III study followed ⁴.
• Cancer chemosensitization: Weekly suramin dosed to a 10-50 µM plasma level with paclitaxel produced an objective response rate of 23% and median progression-free survival of 3.4 months in taxane-pretreated metastatic breast cancer ⁵. A phase I NSCLC study using docetaxel or gemcitabine reported 2 partial responses and 9 stable disease cases, with target plasma levels reached in 90% of treatment courses ⁶.

Preclinical and mechanistic findings

• Antiviral activity: In cell culture, suramin inhibits SARS-CoV-2 with an EC50 near 20 µM by interfering with early replication steps ¹⁵. It also blocks chikungunya, Ebola, enterovirus A71, and Zika virus enzymes in laboratory models ¹⁷.
• Inflammation and tissue protection: Suramin neutralizes histones ²², suppresses cGAS-driven interferon signaling ²³, protects against colitis by targeting PI3K ¹⁰, and reduces osteoarthritis cartilage degradation by raising extracellular TIMP-3 ¹³. In a rat Parkinson's model, it outperformed metformin on several motor and inflammatory measures ¹¹.
• Kidney effects are bidirectional: It reduced diabetic kidney fibrosis markers and improved creatinine clearance in mice ⁸, and protected against cisplatin kidney injury ⁷. But twice-weekly dosing in a polycystic kidney model caused tubular phospholipidosis even while reducing cysts ⁹.
• Cautions: Purinergic antagonism can delay wound healing, angiogenesis, and collagen synthesis in animal models ³⁰.

Human and clinical protocols

Setting	Protocol	Source
Approved HAT	4-5 mg/kg test dose, then 20 mg/kg IV (max 1 g) on days 1, 3, 7, 14, and 21	2
Breast cancer	Weekly IV, nomogram dosed to plasma 10-50 µM, with paclitaxel 80 mg/m²	5
NSCLC	Day 1 of 21-day cycles with docetaxel, or days 1 and 8 with gemcitabine, targeting 10-50 µM	6
Autism (SAT-1)	Single IV infusion of 20 mg/kg	4
Animal models (context only)	Rat Parkinson's 100 mg/kg IV days 11 and 18; PKD mouse 60 mg/kg IP twice weekly; db/db mouse 10 mg/kg IV single dose	8

Animal mg/kg doses do not scale directly to humans. Oncology programs instead used a nomogram to hold plasma levels in the 10-50 µM non-cytotoxic window ⁵.

Timing patterns

• The terminal half-life of roughly 200-289 hours in cattle supports weekly or less frequent dosing ⁴².
• Oral timing is irrelevant because bioavailability is negligible ¹.
• Research protocols avoid dosing around planned surgery because P2 blockade slows wound repair ³⁰.
• Oncology schedules use 21-day cycles until progression ⁵.

Suramin sodium is supplied as a sterile lyophilized powder for injection. It is reconstituted with sterile water for injection and then diluted into 0.9% sodium chloride or 5% dextrose for slow intravenous infusion. Intramuscular pharmacokinetics have been reported in nonhuman primates, but human subcutaneous and intramuscular data are lacking and these routes may cause local irritation; intravenous remains the characterized clinical route. Oral bioavailability is negligible ¹.

The dry powder is stored protected from light at controlled room temperature or refrigerated. Once mixed, the solution should be kept at 2-8°C and protected from light. Because it is given intravenously, clinical pharmacy standards use a 24-48 hour beyond-use window for sterility. This limit reflects microbial risk rather than chemical breakdown: aqueous suramin hydrolyzes very slowly, with only about 2% degradation after 42 days at body temperature ⁵¹. Freeze-thaw cycling of the solution is avoided in research settings.

The interactive calculator below handles the dose and volume conversions for a given vial and requested dose.

Suramin's broad protein binding means interactions are driven by pharmacology rather than liver enzyme metabolism. It shows minimal CYP-type metabolism, so the classic enzyme inhibition and induction interactions are unlikely ¹.

Documented combinations with cancer drugs

• Paclitaxel: Weekly paclitaxel plus suramin was tolerated without dose-limiting toxicities in metastatic breast cancer ⁵.
• Docetaxel: At the full starting dose, febrile neutropenia was dose-limiting in 3 of 6 patients; a reduced docetaxel dose was tolerable ⁶.
• Gemcitabine and docetaxel: Across the combined study population, the regimen was tolerable and produced 2 partial responses and 9 stable disease cases in NSCLC ⁶.
• Cisplatin: In animal models, suramin prevented kidney injury without blocking cisplatin's antitumor activity ⁷.
• Other cancer agents: Preclinical work shows synergy with sunitinib through SP5-VEGFA blockade ²⁶, additive effects with DNA methyltransferase inhibitors ⁵⁸, and sensitization to pevonedistat through IP5K inhibition ²⁴.

Other drug interactions

• Anticoagulants: Suramin therapy has been associated with circulating heparin-like glycosaminoglycan anticoagulants, so bleeding risk with warfarin, heparin, or DOACs is a concern ⁵⁵.
• Corticosteroids and adrenal-directed drugs: Suramin suppresses cortisol secretion in human adrenocortical cells and has caused adrenal insufficiency ⁴³.
• Diuretics: Animal studies show suramin can blunt a GPER1-driven renal sodium excretion pathway via P2Y2 blockade ⁶¹.
• Nimodipine: This calcium-channel blocker partially protected neurons from suramin-induced calcium influx in vitro ²⁹.
• Lysosomotropic drugs: Because suramin accumulates in lysosomes ⁴⁹, combining it with chloroquine, hydroxychloroquine, or amiodarone may add lysosomal stress (theoretical).

Supplements

• N-acetylcysteine: Prevented programmed hypertension in offspring of suramin-treated rats, providing a protective-adjunct lead without human confirmation ⁵⁷.
• EGCG: Showed synergistic antiviral activity against chikungunya in cell culture ⁶⁷.
• Calcitriol: Suramin blocked LL-37-driven macrophage polarization, which enhanced calcitriol's antitumor effect in a mouse liver cancer model ⁶⁶.

Peptide interactions

• LL-37 and similar cationic peptides: Suramin directly complexes the cationic peptide CM15 and blocks LL-37-driven macrophage recruitment and M2 polarization ⁶⁵. Functional cancellation is expected.
• Growth-factor pathway peptides: Suramin blocks FGF1-FGFR2 docking ³⁹ and binds EGF ⁶⁴, so IGF-1, TB-500, or other growth-factor pathway peptides could be antagonized at the signaling level (theoretical).
• Immunomodulatory peptides: Suramin's net immune effect is bidirectional, suppressing cGAS/STING ²³ while potentially releasing Th1 immunity through PCIF1 inhibition ²⁵. No combination studies with thymosin alpha-1 or similar peptides exist.

Cycling for suramin is driven by drug accumulation rather than receptor tolerance. No tachyphylaxis or desensitization has been documented. Instead, the molecule builds up: it binds albumin, enters lysosomes, and has a terminal half-life of roughly 200-289 hours in cattle and weeks in humans ⁴². Repeat dosing without washout raises exposure and end-organ toxicity ¹.

Studied schedules

• Approved HAT treatment is a short course: a small test dose, then 20 mg/kg IV on days 1, 3, 7, 14, and 21 ².
• Oncology protocols use weekly infusions within 21-day cycles until disease progression ⁵.
• The autism pilot used a single IV infusion and a roughly six-week observation window ⁴.
• Community protocols sometimes use single IV doses of 10-20 mg/kg every 4-6 weeks for 1-3 doses per course. No validated on/off cycle exists.

Reasons to pause

Long-term toxicities accumulate with exposure: sensory-motor polyneuropathy ²⁹, hypophosphatemic mitochondrial myopathy ⁵⁰, adrenal insufficiency ⁴³, renal tubular phospholipidosis ⁹, suramin keratosis ⁵², and hematologic suppression ⁶. Research practice treats any toxicity that does not resolve within 2-3 weeks as a signal to widen the interval or stop.

Suramin is rarely stacked outside supervised clinical protocols, and no published evidence supports consumer-level peptide stacks. The useful combination data come from oncology and antiviral research.

Documented combination activity

• With paclitaxel, suramin produced a 23% objective response rate in pretreated metastatic breast cancer ⁵.
• With docetaxel or gemcitabine, it reached target plasma levels in 90% of treatment courses and produced responses or stable disease in most NSCLC patients ⁶.
• With cisplatin, it protected kidneys without reducing tumor kill in animal models ⁷.
• With quinacrine, it increased quinacrine binding roughly eightfold and gave cooperative SARS-CoV-2 3CLpro inhibition in vitro ⁵⁹.
• With EGCG, it showed synergistic anti-chikungunya activity ⁶⁷.
• With calcitriol, blocking LL-37-driven M2 macrophage polarization improved liver cancer outcomes in mice ⁶⁶.
• With DNA methyltransferase inhibitors, it reduced breast cancer cell invasiveness ⁵⁸.

Peptide combinations to avoid

Suramin directly binds and neutralizes cationic antimicrobial peptides such as CM15 and blocks LL-37-driven immune recruitment ⁶⁵. Co-administration with LL-37 is expected to cancel its activity. It also blocks growth-factor receptor interactions, including FGF1-FGFR2 and EGF binding ³⁹, so peptide agents that signal through those pathways could be functionally blunted. For immunomodulatory peptides such as thymosin alpha-1, the net direction is unpredictable because suramin both suppresses cGAS/STING and can release Th1 immunity via PCIF1 ²³.

Suramin is not an FDA-licensed marketed product; its single approved indication is early-stage human African trypanosomiasis caused by Trypanosoma brucei rhodesiense ². Its authorization predates modern NDA frameworks and it is distributed for this indication through the CDC drug service rather than ordinary retail pharmacies. All other uses, including the autism, cancer, and antiviral protocols studied in trials, are investigational ⁴.

It is not a controlled substance. Off-label clinical use requires a prescriber and is typically prepared by compounding pharmacies; import of injectable suramin without a prescription is unlawful in most jurisdictions. Internationally, the drug appears on the WHO Model List of Essential Medicines ² and remains the standard first-stage treatment for T. b. rhodesiense, but non-HAT indications generally require named-patient or compassionate-use routes.

For sport, suramin is not named on the current WADA Prohibited List. Practitioner consensus notes no demonstrated ergogenic effect and advises checking the annual list because non-listed substances can still be captured under category S0 if two of three inclusion criteria apply.

Suramin's safety record depends heavily on exposure. Low-dose protocols targeting 10-50 µM plasma were reasonably well tolerated in phase I/II oncology trials ⁵, and a single low-dose IV infusion was safe in the SAT-1 autism pilot ⁴. Higher cumulative exposure carries a different profile.

Common effects

• Skin reactions: Rash was common in phase I trials ⁶. Distinctive suramin keratosis and keratoacanthoma-like lesions have been reported in long-term oncology use ⁵².
• Blood and metabolic effects: Neutropenia, thrombocytopenia, anemia, fatigue, nausea, hyperglycemia, and electrolyte changes occurred in combination cancer trials ⁶.
• Neuropathy: Sensory-motor polyneuropathy was the dose-limiting toxicity in oncology development ³³. A single 250 mg/kg dose reproduces the syndrome in mice, and calcium-channel blockade offered only partial protection in cell culture ²⁹.
• Kidney injury: Twice-weekly dosing in a mouse polycystic kidney model caused tubular phospholipidosis and injury markers despite reducing cysts ⁹. The human threshold between kidney protection and toxicity is not characterized ⁷.

Less common but serious

• Adrenal insufficiency from cortisol suppression ⁴³
• Coagulopathy from circulating heparin-like glycosaminoglycans ⁵⁵
• Hypophosphatemic muscle weakness linked to mitochondrial toxicity ⁵⁰
• Toxic keratopathy ⁴⁴

Monitoring used in research

Because suramin persists for weeks ⁴², monitoring extends beyond the last dose. Research protocols typically track kidney function, blood counts, phosphate, morning cortisol, coagulation, and plasma suramin levels, and perform neurologic, skin, and eye exams at intervals.